Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

Castiello L, Sestili P, Schiavoni G, Dattilo R, Monque DM, Ciaffoni F, Iezzi M, Lamolinara A, Sistigu A, Moschella F, Pacca AM, Macchia D, Ferrantini M, Zeuner A, Biffoni M, Proietti E, Belardelli F, Aricò E.

Cancer Immunol Res. 2018 Jun;6(6):658-670. doi: 10.1158/2326-6066.CIR-17-0675. Epub 2018 Apr 5.

PMID:
29622580
2.

Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.

Montico B, Lapenta C, Ravo M, Martorelli D, Muraro E, Zeng B, Comaro E, Spada M, Donati S, Santini SM, Tarallo R, Giurato G, Rizzo F, Weisz A, Belardelli F, Dolcetti R, Dal Col J.

Oncoimmunology. 2017 Jul 31;6(11):e1356964. doi: 10.1080/2162402X.2017.1356964. eCollection 2017.

3.

Role of interferon regulatory factor 1 in governing Treg depletion, Th1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide.

Buccione C, Fragale A, Polverino F, Ziccheddu G, Aricò E, Belardelli F, Proietti E, Battistini A, Moschella F.

Int J Cancer. 2018 Mar 1;142(5):976-987. doi: 10.1002/ijc.31083. Epub 2017 Oct 16.

PMID:
28975621
4.

Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells.

Fragale A, Romagnoli G, Licursi V, Buoncervello M, Del Vecchio G, Giuliani C, Parlato S, Leone C, De Angelis M, Canini I, Toschi E, Belardelli F, Negri R, Capone I, Presutti C, Gabriele L.

Cancer Immunol Res. 2017 Jul;5(7):604-616. doi: 10.1158/2326-6066.CIR-17-0080. Epub 2017 Jun 14.

5.

Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis.

Aricò E, Sestili P, Carpinelli G, Canese R, Cecchetti S, Schiavoni G, D'Urso MT, Belardelli F, Proietti E.

Oncotarget. 2016 Sep 13;7(37):59754-59765. doi: 10.18632/oncotarget.10880.

6.

NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients.

Lapenta C, Donati S, Spadaro F, Castaldo P, Belardelli F, Cox MC, Santini SM.

J Immunol. 2016 Aug 1;197(3):795-806. doi: 10.4049/jimmunol.1600262. Epub 2016 Jun 29.

7.
8.

International Accreditation of Cancer Centres of Italian Network of Alleanza contro il Cancro: introductory remarks.

Paradiso A, Belardelli F, De Paoli P, De Maria R.

Tumori. 2015;101 Suppl 1:1. doi: 10.5301/tj.5000454. Epub 2015 Dec 30. No abstract available.

PMID:
27096263
9.

IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.

Buoncervello M, Romagnoli G, Buccarelli M, Fragale A, Toschi E, Parlato S, Lucchetti D, Macchia D, Spada M, Canini I, Sanchez M, Falchi M, Musella M, Biffoni M, Belardelli F, Capone I, Sgambato A, Vitiani LR, Gabriele L.

Oncotarget. 2016 May 3;7(18):26361-73. doi: 10.18632/oncotarget.8379.

10.

European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk.

Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, Romieu I, Segnan N, Wardle J, Wiseman M, Belardelli F, Bettcher D, Cavalli F, Galea G, Lenoir G, Martin-Moreno JM, Nicula FA, Olsen JH, Patnick J, Primic-Zakelj M, Puska P, van Leeuwen FE, Wiestler O, Zatonski W; Working Groups of Scientific Experts.

Cancer Epidemiol. 2015 Dec;39 Suppl 1:S1-10. doi: 10.1016/j.canep.2015.05.009. Epub 2015 Jul 9.

11.

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.

Rozera C, Cappellini GA, D'Agostino G, Santodonato L, Castiello L, Urbani F, Macchia I, Aricò E, Casorelli I, Sestili P, Montefiore E, Monque D, Carlei D, Napolitano M, Rizza P, Moschella F, Buccione C, Belli R, Proietti E, Pavan A, Marchetti P, Belardelli F, Capone I.

J Transl Med. 2015 May 2;13:139. doi: 10.1186/s12967-015-0473-5.

12.

A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Torelli GF, Rozera C, Santodonato L, Peragine N, D'agostino G, Montefiore E, Napolitano MR, Monque DM, Carlei D, Mariglia P, Pauselli S, Gozzer M, Bafti MS, Girelli G, Guarini A, Belardelli F, Foà R.

Blood Transfus. 2015 Jul;13(3):464-71. doi: 10.2450/2015.0231-14. Epub 2015 Jan 30.

13.

Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells.

Anastasiadou E, Garg N, Bigi R, Yadav S, Campese AF, Lapenta C, Spada M, Cuomo L, Botta A, Belardelli F, Frati L, Ferretti E, Faggioni A, Trivedi P.

Int J Cancer. 2015 Sep 15;137(6):1491-7. doi: 10.1002/ijc.29489. Epub 2015 Mar 4.

14.

Interferon fundamentals: a tribute to the scientific vision of G B Rossi. Editorial.

Battistini A, Coccia EM, Belardelli F.

Cytokine Growth Factor Rev. 2015 Apr;26(2):95-7. doi: 10.1016/j.cytogfr.2014.12.003. Epub 2014 Dec 26. No abstract available.

PMID:
25578521
15.

Role of type I interferon in inducing a protective immune response: perspectives for clinical applications.

Rizza P, Moretti F, Capone I, Belardelli F.

Cytokine Growth Factor Rev. 2015 Apr;26(2):195-201. doi: 10.1016/j.cytogfr.2014.10.002. Epub 2014 Oct 30. Review.

PMID:
25466627
16.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L.

Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.

PMID:
25344738
17.

A semi-automatic web based tool for the selection of research projects reviewers.

Pupella V, Monteverde ME, Lombardo C, Belardelli F, Giacomini M.

Stud Health Technol Inform. 2014;205:950-4.

PMID:
25160328
18.

Development of a pilot project on data sharing among partners of the Italian Hub of Population Biobanks (HIBP): association between lipid profile and socio-demographic variables.

Napolitano M, Santoro F, Puopolo M, Donfancesco C, Galluzzo L, De Grandi A, Cevenini E, De Curtis A, Sevini F, Palmieri L, Mascalzon D, Roazzi P, Scafato E, Pramstaller P, Iacoviello L, Donati MB, Giampaoli S, Franceschi C, Belardelli F, Bravo E.

Biopreserv Biobank. 2014 Aug;12(4):225-33. doi: 10.1089/bio.2014.0001. Epub 2014 Jul 30.

PMID:
25075723
19.

The European Research Infrastructures of the ESFRI Roadmap in Biological and Medical Sciences: status and perspectives.

Calzolari A, Valerio A, Capone F, Napolitano M, Villa M, Pricci F, Bravo E, Belardelli F.

Ann Ist Super Sanita. 2014;50(2):178-85. doi: DOI: 10.4415/ANN_14_02_12.

20.

Type I interferons as regulators of human antigen presenting cell functions.

Gessani S, Conti L, Del Cornò M, Belardelli F.

Toxins (Basel). 2014 May 26;6(6):1696-723. doi: 10.3390/toxins6061696. Review.

21.

A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells.

Mattei F, Schiavoni G, De Ninno A, Lucarini V, Sestili P, Sistigu A, Fragale A, Sanchez M, Spada M, Gerardino A, Belardelli F, Businaro L, Gabriele L.

J Immunotoxicol. 2014 Oct;11(4):337-46. doi: 10.3109/1547691X.2014.891677. Epub 2014 Mar 6.

PMID:
24597645
22.

Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers.

Deriu PL, La Pietra L, Pierotti M, Collazzo R, Paradiso A, Belardelli F, De Paoli P, Nigro A, Lacalamita R, Ferrarini M, Pelicci P, Pierotti M, Roli A, Ciliberto G, Scala S, Amadori A, Chiusole D, Musto P, Fusco V, Storto G, De Maria R, Canitano S, Apolone G, Ravelli M, Mazzini E, Amadori D, Bernabini M, Ancarani V, Lombardo C.

Tumori. 2013 Nov-Dec;99(6):293e-8e. doi: 10.1700/1390.15472.

23.

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012.

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Parisi G, Cutaia O, Fonsatti E, Parmiani G.

Cancer Immunol Immunother. 2013 Dec;62(12):1851-8. doi: 10.1007/s00262-013-1496-5. Epub 2013 Nov 5. No abstract available.

PMID:
24190546
24.

Exploiting dendritic cells in the development of cancer vaccines.

Bracci L, Capone I, Moschella F, Proietti E, Belardelli F.

Expert Rev Vaccines. 2013 Oct;12(10):1195-210. doi: 10.1586/14760584.2013.836905. Epub 2013 Oct 4. Review.

PMID:
24090117
25.

Opposite regulatory effects of IFN-β and IL-3 on C-type lectin receptors, antigen uptake, and phagocytosis in human macrophages.

Cardone M, Ikeda KN, Varano B, Belardelli F, Millefiorini E, Gessani S, Conti L.

J Leukoc Biol. 2014 Jan;95(1):161-8. doi: 10.1189/jlb.0313168. Epub 2013 Sep 9.

PMID:
24018352
26.

IFN-α regulates Blimp-1 expression via miR-23a and miR-125b in both monocytes-derived DC and pDC.

Parlato S, Bruni R, Fragapane P, Salerno D, Marcantonio C, Borghi P, Tataseo P, Ciccaglione AR, Presutti C, Romagnoli G, Bozzoni I, Belardelli F, Gabriele L.

PLoS One. 2013 Aug 16;8(8):e72833. doi: 10.1371/journal.pone.0072833. eCollection 2013.

27.

The Italian Hub of Population Biobanks as a potential tool for improving public health stewardship.

Bravo E, Napolitano M, Santoro F, Belardelli F, Federic A.

Biopreserv Biobank. 2013 Jun;11(3):173-5.

28.

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.

Bracci L, Schiavoni G, Sistigu A, Belardelli F.

Cell Death Differ. 2014 Jan;21(1):15-25. doi: 10.1038/cdd.2013.67. Epub 2013 Jun 21. Review.

29.

Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy.

Moschella F, Torelli GF, Valentini M, Urbani F, Buccione C, Petrucci MT, Natalino F, Belardelli F, Foà R, Proietti E.

Clin Cancer Res. 2013 Aug 1;19(15):4249-61. doi: 10.1158/1078-0432.CCR-12-3666. Epub 2013 Jun 12.

30.

Interferon regulatory factor 8-deficiency determines massive neutrophil recruitment but T cell defect in fast growing granulomas during tuberculosis.

Rocca S, Schiavoni G, Sali M, Anfossi AG, Abalsamo L, Palucci I, Mattei F, Sanchez M, Giagu A, Antuofermo E, Fadda G, Belardelli F, Delogu G, Gabriele L.

PLoS One. 2013 May 24;8(5):e62751. doi: 10.1371/journal.pone.0062751. Print 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/cbf9ae84-2f74-4d4d-b2e7-b39e7ebaaaa8.

31.

IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.

Mattei F, Schiavoni G, Sestili P, Spadaro F, Fragale A, Sistigu A, Lucarini V, Spada M, Sanchez M, Scala S, Battistini A, Belardelli F, Gabriele L.

Neoplasia. 2012 Dec;14(12):1223-35.

32.

Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment.

Businaro L, De Ninno A, Schiavoni G, Lucarini V, Ciasca G, Gerardino A, Belardelli F, Gabriele L, Mattei F.

Lab Chip. 2013 Jan 21;13(2):229-39. doi: 10.1039/c2lc40887b. Epub 2012 Oct 30.

PMID:
23108434
33.
34.

Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer.

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Parisi G, Fonsatti E, Papamichail M, Parmiani G; NIBIT.

Cancer Immunol Immunother. 2012 Sep;61(9):1599-608. Epub 2012 Jun 27. No abstract available.

PMID:
22736255
35.

Interferon-α as antiviral and antitumor vaccine adjuvants: mechanisms of action and response signature.

Aricò E, Belardelli F.

J Interferon Cytokine Res. 2012 Jun;32(6):235-47. doi: 10.1089/jir.2011.0077. Epub 2012 Apr 10. Review.

PMID:
22490303
36.

IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.

Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F, Santini SM, Ferrantini M.

Blood. 2012 Feb 9;119(6):1407-17. doi: 10.1182/blood-2011-06-363564. Epub 2011 Dec 19.

37.

Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.

Proietti E, Moschella F, Capone I, Belardelli F.

Mol Oncol. 2012 Feb;6(1):1-14. doi: 10.1016/j.molonc.2011.11.005. Epub 2011 Dec 3. Review.

38.

TRAIN: Training through Research Application Italian iNitiative.

Lombardo C, Bottero S, d'Alessandro F, Giacomini M, Guderzo A, Moretti F, Marincola M, Pesce G, Pierotti MA, Spagnoli LG, Belardelli F.

Int J Biol Markers. 2011 Apr-Jun;26(2):136-8. doi: 10.5301/JBM.2011.8377.

PMID:
21623583
39.

Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments.

Aricò E, Castiello L, Urbani F, Rizza P, Panelli MC, Wang E, Marincola FM, Belardelli F.

J Transl Med. 2011 May 17;9:67. doi: 10.1186/1479-5876-9-67.

40.

IFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use.

Rizza P, Capone I, Moretti F, Proietti E, Belardelli F.

Expert Rev Vaccines. 2011 Apr;10(4):487-98. doi: 10.1586/erv.11.9. Review.

PMID:
21506646
41.

MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68.

Aricò E, Monque DM, D'Agostino G, Moschella F, Venditti M, Kalinke U, Allen DJ, Stewart JP, Nash AA, Belardelli F, Ferrantini M.

Vaccine. 2011 May 23;29(23):3935-44. doi: 10.1016/j.vaccine.2011.03.092. Epub 2011 Apr 8. Erratum in: Vaccine. 2012 Apr 26;30(20):3145. Stewart, James P [added].

PMID:
21481326
42.

Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide.

Moschella F, Valentini M, Aricò E, Macchia I, Sestili P, D'Urso MT, Alessandri C, Belardelli F, Proietti E.

Cancer Res. 2011 May 15;71(10):3528-39. doi: 10.1158/0008-5472.CAN-10-4523. Epub 2011 Mar 28.

43.

Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.

Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, Spada M, Belardelli F, Gabriele L, Schiavoni G.

J Immunol. 2011 May 1;186(9):5142-50. doi: 10.4049/jimmunol.1004163. Epub 2011 Mar 25.

44.

Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010.

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E; NIBIT, Parmiani G.

Cancer Immunol Immunother. 2011 Jun;60(6):901-7. doi: 10.1007/s00262-011-1006-6. Epub 2011 Mar 24. No abstract available.

PMID:
21431916
45.

Translational research on advanced therapies.

Belardelli F, Rizza P, Moretti F, Carella C, Galli MC, Migliaccio G.

Ann Ist Super Sanita. 2011;47(1):72-8. doi: 10.4415/ANN_11_01_15. Review.

46.

Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12.

Santini SM, Lapenta C, Donati S, Spadaro F, Belardelli F, Ferrantini M.

PLoS One. 2011 Feb 28;6(2):e17364. doi: 10.1371/journal.pone.0017364.

47.

Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis.

Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, Gabriele L, Proietti E, Bracci L.

Cancer Res. 2011 Feb 1;71(3):768-78. doi: 10.1158/0008-5472.CAN-10-2788. Epub 2010 Dec 13.

48.

IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity.

Lattanzi L, Rozera C, Marescotti D, D'Agostino G, Santodonato L, Cellini S, Belardelli F, Gavioli R, Ferrantini M.

Immunobiology. 2011 May;216(5):537-47. doi: 10.1016/j.imbio.2010.10.003. Epub 2010 Oct 21.

PMID:
21093097
49.

Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.

Palermo B, Del Bello D, Sottini A, Serana F, Ghidini C, Gualtieri N, Ferraresi V, Catricalà C, Belardelli F, Proietti E, Natali PG, Imberti L, Nisticò P.

Cancer Res. 2010 Sep 15;70(18):7084-92. doi: 10.1158/0008-5472.CAN-10-1326. Epub 2010 Sep 7.

50.

Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.

Moschella F, Proietti E, Capone I, Belardelli F.

Ann N Y Acad Sci. 2010 Apr;1194:169-78. doi: 10.1111/j.1749-6632.2010.05464.x. Review.

PMID:
20536466

Supplemental Content

Loading ...
Support Center